Medical and health sciences
- Non-clinical studies
- Small molecules
- Cancer therapy
- Respiratory medicine
In the Amalus drug discovery program (StepStone), we pursue the establishment of a spin-off company to progress cell-selective inhibitors to clinical trials. This ConcepTT project will increase the IP and investment value of the program.
Our inhibitors possess unique features with respect to competition and represent a first-in-class opportunity.
As single agents, our molecules inhibit metastasis in vivo. In the StepStone project, we now focus on growth and metastasis in combination with anti-proliferatives.
Recent data shows that our inhibitors cause remarkable cellular effects in vivo, which may answer unmet needs in two additional applications:
- Combination with checkpoint inhibitors: our compounds may render additional indications responsive to immunotherapy.
- Fibrosis: they may constitute a well-tolerated solution to revert progression.
The Stepstone funding does not cover these new opportunities. This ConcepTT project, therefore, aims to generate in vivo proof-of-mechanism and efficacy for pulmonary fibrosis (stand-alone) and breast cancer (combined with a checkpoint inhibitor).